Ginkgo Bioworks Holdings (DNA) Operating Margin (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Operating Margin of 366.51% for Q1 2026, down 73.0% on a QoQ basis from 211.86% in Q4 2025, and down 15471.0% year-over-year from N/an in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Operating Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Operating Margin history runs 7 years deep, the most recent figure standing at 366.51% for Q1 2026.
- Quarterly Operating Margin fell 15471.0% year-over-year to 366.51% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 210.66% (down 711.0% YoY) and the FY2025 annual result came in at 185.29%, up 6125.0% from the prior year.
- Operating Margin was 366.51% for Q1 2026 at Ginkgo Bioworks Holdings, down from 211.86% in the prior quarter.
- Across five years, Operating Margin topped out at 61.99% in Q3 2024 and bottomed at 986.38% in Q3 2022.
- A 5-year average of 322.01% and a median of 236.29% in 2024 frame the typical range for Operating Margin.
- Peak annual rise in Operating Margin reached 89966 bps in 2022, while the deepest fall reached 95202 bps in 2022.
- Ginkgo Bioworks Holdings' Operating Margin stood at 234.89% in 2022, then jumped by 69 bps to 73.27% in 2023, then sank by 222 bps to 236.29% in 2024, then grew by 10 bps to 211.86% in 2025, then slumped by 73 bps to 366.51% in 2026.
- Business Quant data shows DNA's Operating Margin at 366.51% in Q1 2026, 211.86% in Q4 2025, and 231.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | -366.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -366.51% |
| Dec 31, 2025 | -211.86% |
| Sep 30, 2025 | -231.78% |
| Jun 30, 2025 | -132.13% |
| Mar 31, 2025 | -211.80% |
| Dec 31, 2024 | -236.29% |
| Sep 30, 2024 | -61.99% |
| Jun 30, 2024 | -396.66% |
| Mar 31, 2024 | -469.12% |
| Dec 31, 2023 | -73.27% |
| Sep 30, 2023 | -516.68% |
| Jun 30, 2023 | -228.57% |
| Mar 31, 2023 | -267.34% |
| Dec 31, 2022 | -234.89% |
| Sep 30, 2022 | -986.38% |
| Jun 30, 2022 | -447.92% |
| Mar 31, 2022 | -401.04% |
| Dec 31, 2021 | -1,134.55% |
| Sep 30, 2021 | -34.37% |
| Jun 30, 2021 | -137.38% |